

- S1. Whary, M.T., and Fox, J.G. 2004. Natural and experimental *Helicobacter* infections. *Comp Med* **54**:128-158.
- S2. Blaser, M.J., and Kirschner, D. 2007. The equilibria that allow bacterial persistence in human hosts. *Nature* **449**:843-849.
- S3. Gewirtz, A.T., et al. 2004. *Helicobacter pylori* flagellin evades toll-like receptor 5-mediated innate immunity. *J Infect Dis* **189**:1914-1920.
- S4. Atherton, J.C. 2006. The pathogenesis of *Helicobacter pylori*-induced gastroduodenal disease. *Annu Rev Pathol Mech Dis* **1**:63-96.
- S5. Tammer, I., Brandt, S., Hartig, R., Konig, W., and Backert, S. 2007. Activation of Abl by *Helicobacter pylori*: a novel kinase for CagA and crucial mediator of host cell scattering. *Gastroenterology* **132**:1309-1319.
- S6. Rohde, M., Puls, J., Buhrdorf, R., Fischer, W., and Haas, R. 2003. A novel sheathed surface organelle of the *Helicobacter pylori* cag type IV secretion system. *Mol Microbiol* **49**:219-234.
- S7. Correa, P. 1996. *Helicobacter pylori* and gastric cancer: state of the art. *Cancer Epidemiol Biomarkers Prev* **5**:477-481.
- S8. Gangwer, K.A., et al. 2007. Crystal structure of the *Helicobacter pylori* vacuolating toxin p55 domain. *Proc Natl Acad Sci USA* **104**:16293-16298.
- S9. Tombola, F., et al. 1999. *Helicobacter pylori* vacuolating toxin forms anion-selective channels in planar lipid bilayers: possible implications for the mechanism of cellular vacuolation. *Biophys J* **76**:1401-1409.
- S10. Yahiro, K., et al. 2003. Protein-tyrosine phosphatase alpha, RPTP alpha, is a *Helicobacter pylori* VacA receptor. *J Biol Chem* **278**:19183-19189.
- S11. Boncristiano, M., et al. 2003. The *Helicobacter pylori* vacuolating toxin inhibits T cell activation by two independent mechanisms. *J Exp Med* **198**:1887-1897.
- S12. Sundrud, M.S., Torres, V.J., Unutmaz, D., and Cover, T.L. 2004. Inhibition of primary human T cell proliferation by *Helicobacter pylori* vacuolating toxin (VacA) is independent of VacA effects on IL-2 secretion. *Proc Natl Acad Sci USA* **101**:7727-7732.
- S13. Atherton, J.C., Peek, R.M., Jr., Tham, K.T., Cover, T.L., and Blaser, M.J. 1997. Clinical and pathological importance of heterogeneity in vacA, the vacuolating cytotoxin gene of *Helicobacter pylori*. *Gastroenterology* **112**:92-99.
- S14. Kidd, M., Lastovica, A.J., Atherton, J.C., and Louw, J.A. 1999. Heterogeneity in the *Helicobacter pylori* vacA and cagA genes: association with gastroduodenal disease in South Africa? *Gut* **45**:499-502.
- S15. Miehlike, S., et al. 2000. The *Helicobacter pylori* vacA s1, m1 genotype and cagA is associated with gastric carcinoma in Germany. *Int J Cancer* **87**:322-327.
- S16. Figueiredo, C., et al. 2001. *Helicobacter pylori* genotypes are associated with clinical outcome in Portuguese patients and show a high prevalence of infections with multiple strains. *Scand J Gastroenterol* **36**:128-135.
- S17. Ito, Y., et al. 1998. Full-length sequence analysis of the vacA gene from cytotoxic and noncytotoxic *Helicobacter pylori*. *J Infect Dis* **178**:1391-1398.
- S18. Prinz, C., et al. 2001. Key importance of the *Helicobacter pylori* adherence factor blood group antigen binding adhesin during chronic gastric inflammation. *Cancer Res* **61**:1903-1909.
- S19. Chang, Y.J., et al. 2006. Mechanisms for *Helicobacter pylori* CagA-induced cyclin D1 expression that affect cell cycle. *Cell Microbiol* **8**:1740-1752.
- S20. Argent, R.H., Burette, A., Miendje Deyi, V.Y., and Atherton, J.C. 2007. The presence of dupA in *Helicobacter pylori* is not significantly associated with duodenal ulceration in Belgium, South Africa, China, or North America. *Clin Infect Dis* **45**:1204-1206.

- S21. Douraghi, M., et al. 2008. dupA as a risk determinant in *Helicobacter pylori* infection. *J Med Microbiol* **57**:554-562.
- S22. Zhang, Z., et al. 2008. The *Helicobacter pylori* duodenal ulcer promoting gene, dupA in China. *BMC Gastroenterol* **8**:49.
- S23. Alm, R.A., et al. 1999. Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen *Helicobacter pylori*. *Nature* **397**:176-180.
- S24. Oh, J.D., et al. 2006. The complete genome sequence of a chronic atrophic gastritis *Helicobacter pylori* strain: evolution during disease progression. *Proc Natl Acad Sci USA* **103**:9999-10004.
- S25. Baltrus, D.A., et al. 2009. The complete genome sequence of *Helicobacter pylori* strain G27. *J Bacteriol* **191**:447-448.
- S26. Kang, J., and Blaser, M.J. 2008. Repair and antirepair DNA helicases in *Helicobacter pylori*. *J Bacteriol* **190**:4218-4224.
- S27. Kang, J.M., Iovine, N.M., and Blaser, M.J. 2006. A paradigm for direct stress-induced mutation in prokaryotes. *Faseb J* **20**:2476-2485.
- S28. Sanabria-Valentin, E., Colbert, M.T., and Blaser, M.J. 2007. Role of futC slipped strand mispairing in *Helicobacter pylori* Lewisy phase variation. *Microbes Infect* **9**:1553-1560.
- S29. Huang, S., Kang, J., and Blaser, M.J. 2006. Antimutator role of the DNA glycosylase mutY gene in *Helicobacter pylori*. *J Bacteriol* **188**:6224-6234.
- S30. Kang, J., and Blaser, M.J. 2006. Bacterial populations as perfect gases: genomic integrity and diversification tensions in *Helicobacter pylori*. *Nat Rev Microbiol* **4**:826-836.
- S31. Webb, G.F., and Blaser, M.J. 2002. Dynamics of bacterial phenotype selection in a colonized host. *Proc Natl Acad Sci USA* **99**:3135-3140.
- S32. Ghose, C., Perez-Perez, G.I., van Doorn, L.J., Dominguez-Bello, M.G., and Blaser, M.J. 2005. High frequency of gastric colonization with multiple *Helicobacter pylori* strains in Venezuelan subjects. *J Clin Microbiol* **43**:2635-2641.
- S33. Rader, B.A., Campagna, S.R., Semmelhack, M.F., Bassler, B.L., and Guillemin, K. 2007. The quorum-sensing molecule autoinducer 2 regulates motility and flagellar morphogenesis in *Helicobacter pylori*. *J Bacteriol* **189**:6109-6117.
- S34. Torok, A.M., Bouton, A.H., and Goldberg, J.B. 2005. *Helicobacter pylori* induces interleukin-8 secretion by Toll-like receptor 2- and Toll-like receptor 5-dependent and -independent pathways. *Infect Immun* **73**:1523-1531.
- S35. Machado, J.C., increased risk of gastric carcinoma. *Gastroenterology* **121**:823-829.
- S36. Robinson, K., Argent, R.H., and Atherton, J.C. 2007. The inflammatory and immune response to *Helicobacter pylori* infection. *Best Pract Res Clin Gastroenterol* **21**:237-259.
- S37. Garhart, C.A., Nedrud, J.G., Heinzl, F.P., Sigmund, N.E., and Czinn, S.J. 2003. Vaccine-induced protection against *Helicobacter pylori* in mice lacking both antibodies and interleukin-4. *Infect Immun* **71**:3628-3633.
- S38. Bamford, K.B., et al. 1998. Lymphocytes in the human gastric mucosa during *Helicobacter pylori* have a T helper cell 1 phenotype. *Gastroenterology* **114**:482-492.
- S39. Stoicov, C., et al. 2004. Coinfection modulates inflammatory responses and clinical outcome of *Helicobacter felis* and *Toxoplasma gondii* infections. *J Immunol* **173**:3329-3336.
- S40. Cui, G.L., Houghton, J., Finkel, N., Carlson, J., and Wang, T.C. 2003. IFN-gamma infusion induces gastric atrophy, metaplasia and dysplasia in the absence of *Helicobacter* infection - a role for immune response in *Helicobacter* disease. *Gastroenterology* **124**:A19-A19.

- S41. Itoh, T., et al. 1999. The vast majority of gastric T cells are polarized to produce T helper 1 type cytokines upon antigenic stimulation despite the absence of *Helicobacter pylori* infection. *J Gastroenterol* **34**:560-570.
- S42. Paziak-Domanska, B., Chmiela, M., Jarosinska, A., and Rudnicka, W. 2000. Potential role of CagA in the inhibition of T cell reactivity in *Helicobacter pylori* infections. *Cell Immunol* **202**:136-139.
- S43. Lindholm, C., et al. 1998. Local cytokine response in *Helicobacter pylori*-infected subjects. *Infect Immun* **66**:5964-5971.
- S44. Stromberg, E., et al. 2005. Down-regulation of epithelial IL-8 responses in *Helicobacter pylori*-infected duodenal ulcer patients depends on host factors, rather than bacterial factors. *Clin Exp Immunol* **140**:117-125.
- S45. Chen, W., Shu, D., and Chadwick, V.S. 2001. *Helicobacter pylori* infection: mechanism of colonization and functional dyspepsia Reduced colonization of gastric mucosa by *Helicobacter pylori* in mice deficient in interleukin-10. *J Gastroenterol Hepatol* **16**:377-383.
- S46. Sonnenberg, A. 2007. Time trends of ulcer mortality in non-European countries. *Am J Gastroenterol* **102**:1101-1107
- S47. Van Zanten, S.J., Dixon, M.F., and Lee, A. 1999. The gastric transitional zones: neglected links between gastroduodenal pathology and *helicobacter* ecology. *Gastroenterology* **116**:1217-1229.
- S48. Lauren, P. 1965. The Two Histological Main Types of Gastric Carcinoma: Diffuse and So-Called Intestinal-Type Carcinoma. an Attempt at a Histo-Clinical Classification. *Acta Pathol Microbiol Scand* **64**:31-49.
- S49. Brinton, L.A., Gridley, G., Hrubec, Z., Hoover, R., and Fraumeni, J.F., Jr. 1989. Cancer risk following pernicious anaemia. *Br J Cancer* **59**:810-813.
- S50. Leung, W.K., et al. 2004. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on *Helicobacter pylori* eradication. *Gut* **53**:1244-1249.
- S51. Abraham, S.C., Nobukawa, B., Giardiello, F.M., Hamilton, S.R., and Wu, T.T. 2001. Sporadic fundic gland polyps: common gastric polyps arising through activating mutations in the beta-catenin gene. *Am J Pathol* **158**:1005-1010.
- S52. Du, M.Q., and Atherton, J.C. 2006. Molecular subtyping of gastric MALT lymphomas: implications for prognosis and management. *Gut* **55**:886-893.
- S53. Fischbach, W., Goebeler-Kolve, M.E., Dragosics, B., Greiner, A., and Stolte, M. 2004. Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive *Helicobacter pylori* eradication therapy: experience from a large prospective series. *Gut* **53**:34-37
- S54. Kaye, P.V., et al. 2008. The Clinical Utility and Diagnostic Yield of Routine Gastric Biopsies in the Investigation of Iron Deficiency Anemia: A Case-Control Study. *Am J Gastroenterol*. **103**: 2883-2889
- S55. Khitam Muhsen, D.C. 2008. *Helicobacter pylori* Infection and Iron Stores: A Systematic Review and Meta-analysis. *Helicobacter* **13**:323-340
- S56. Sipponen, P., Laxen, F., Huotari, K., and Harkonen, M. 2003. Prevalence of low vitamin B12 and high homocysteine in serum in an elderly male population: association with atrophic gastritis and *Helicobacter pylori* infection. *Scand J Gastroenterol* **38**:1209-1216.
- S57. Hershko, C., et al. 2005. Role of autoimmune gastritis, *Helicobacter pylori* and celiac disease in refractory or unexplained iron deficiency anemia. *Haematologica* **90**:585-595.

- S58. Rostami, N., Keshtkar-Jahromi, M., Rahnavardi, M., Keshtkar-Jahromi, M., and Esfahani, F.S. 2008. Effect of eradication of *Helicobacter pylori* on platelet recovery in patients with chronic idiopathic thrombocytopenic purpura: a controlled trial. *Am J Hematol* **83**:376-381.
- S59. El-Omar, E.M., et al. 1997. *Helicobacter pylori* infection and chronic gastric acid hyposecretion. *Gastroenterology* **113**:15-24.
- S60. el-Omar, E.M., et al. 1995. *Helicobacter pylori* infection and abnormalities of acid secretion in patients with duodenal ulcer disease. *Gastroenterology* **109**:681-691
- S61. Atherton, J. 2008. Does *Helicobacter pylori* protect against oesophageal adenocarcinoma, and if so, how? *Clin Med* **8**:420-422.
- S62. Abe, Y., et al. 2004. The prevalence of *Helicobacter pylori* infection and the status of gastric acid secretion in patients with Barrett's esophagus in Japan. *Am J Gastroenterol* **99**:1213-1221.
- S63. Warburton-Timms, V.J., et al. 2001. The significance of cagA(+) *Helicobacter pylori* in reflux oesophagitis. *Gut* **49**:341-346.
- S64. Ando, T., et al. 2006. Interleukin 1B proinflammatory genotypes protect against gastro-oesophageal reflux disease through induction of corpus atrophy. *Gut* **55**:158-164.
- S65. Takeuchi, R., et al. 2004. Abnormal gastroesophageal flap valve is highly associated with endoscopic reflux esophagitis after *Helicobacter pylori* eradication. *Helicobacter* **9**:1-8.
- S66. Inoue, H., et al. 2004. Reflux esophagitis after eradication of *Helicobacter pylori* is associated with the degree of hiatal hernia. *Scand J Gastroenterol* **39**:1061-1065.
- S67. Delaney, B., and McColl, K. 2005. Review article: *Helicobacter pylori* and gastro-oesophageal reflux disease. *Aliment Pharmacol Ther* **22 Suppl 1**:32-40.
- S68. Zhang, Y., et al. 1994. Positional cloning of the mouse obese gene and its human homologue. *Nature* **372**:425-432.
- S69. Friedman, J.M., and Halaas, J.L. 1998. Leptin and the regulation of body weight in mammals. *Nature* **395**:763-770.
- S70. Kojima, M., et al. 1999. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. *Nature* **402**:656-660.
- S71. Tschop, M., Smiley, D.L., and Heiman, M.L. 2000. Ghrelin induces adiposity in rodents. *Nature* **407**:908-913.
- S72. Tatsuguchi, A., et al. 2004. Effect of *Helicobacter pylori* infection on ghrelin expression in human gastric mucosa. *Am J Gastroenterol* **99**:2121-2127.
- S73. Shiotani, A., Miyanishi, T., Uedo, N., and Iishi, H. 2005. *Helicobacter pylori* infection is associated with reduced circulating ghrelin levels independent of body mass index. *Helicobacter* **10**:373-378.
- S74. Yang, Y.J., Sheu, B.S., Lee, S.C., Yang, H.B., and Wu, J.J. 2005. Children of *Helicobacter pylori*-infected dyspeptic mothers are predisposed to H. pylori acquisition with subsequent iron deficiency and growth retardation. *Helicobacter* **10**:249-255.
- S75. Blaser, M.J. 2006. Who are we? Indigenous microbes and the ecology of human diseases. *EMBO Rep* **7**:956-960.
- S76. Yazdanbakhsh, M., Kremsner, P.G., and van Ree, R. 2002. Allergy, parasites, and the hygiene hypothesis. *Science* **296**:490-494.
- S77. McCune, A., et al. 2003. Reduced risk of atopic disorders in adults with *Helicobacter pylori* infection. *Eur J Gastroenterol Hepatol* **15**:637-640.

- S78. Kosunen, T.U., et al. 2002. Increase of allergen-specific immunoglobulin E antibodies from 1973 to 1994 in a Finnish population and a possible relationship to *Helicobacter pylori* infections. *Clin Exp Allergy* **32**:373-378.
- S79. Mendall, M.A., et al. 1992. Childhood living conditions and *Helicobacter pylori* seropositivity in adult life. *Lancet* **339**:896-897.
- S80. Robinson, K., and Atherton, J.C. In Press. *Helicobacter Pylori*.
- S81. Kenefeck, R.M.W., Atherton, J.C., and Robinson, K. 2007. Human *helicobacter pylori* infection induces CD4⁺ CD25^{hi} IL-10⁺ regulatory T-cells in the peripheral blood. *Zoonoses and Public Health* **54**:150